Discover our R&D programs
Contact an expert
ETAP-LAB anticipates market developments and invests a significant portion of its revenue in major R&D programs, led in partnership with academic and industrial experts.
This forward-looking approach enables us to provide cutting-edge preclinical models.
ETAP-LAB is currently working on four research projects funded by the French government, regional authorities, and the European Union: BIO-DIAMOND, STROKTURA, BRYOFLAM et B4B.
BIO-DIAMOND
2022-2025 | Total budget: €5,003,710 | Extended to 2026
BIO-DIAMOND is an industrial demonstrator of the potential of organs-on-chips for the routine evaluation of drug candidates in the discovery and lead optimization phases. One of the project’s main goals is to validate innovative models of Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) in the microfluidic devices of NETRI (project partner), which are compatible with automated HCS tools, thus ensuring predictable and repeatable conditions for medium-throughput screening.
Bio-Diamond is helping to accelerate the adoption of new approach methodologies (NAMs) by the pharmaceutical industry and to reduce animal use in scientific research.
BIO-DIAMOND won the bid for the “Innovations in Biotherapies and Bioproduction” call for projects and has been awarded financial support from the French government as part of the France 2030 and France Relance programs, as well as from the European Union (NextGenerationEU).
STROKTURA – Stroke for the Future
2023-2026 | Total budget: €356,820 | Extended to 2027
Stroktura aims to develop innovative brain imaging solutions applied to preclinical stroke models. This project is led by a world-class consortium of experts from the academic and private sectors: ETAP-LAB, PhIND (INSERM U1237), Cyceron, ESR3P and BB@C.
Based in one of France’s most successful medical research centers specializing in stroke, we are developing innovative animal models combined with cutting-edge imaging technologies (molecular MRI) to improve the evaluation of drug candidate efficacy and safety.
This program has been awarded financial support from the European Union (ERDF) and the Normandy regional authority, consolidating STROK@LLIANCE’s position as a leader in the preclinical CRO market for stroke research.
BRYOFLAM
2022-2025 | Total budget: €1,233,760 | Extended to 2026
The aim of the BRYOFLAM project is to discover new plant-based compounds that could be future candidates for treating peripheral inflammatory diseases or neuroinflammation in neurodegenerative disorders.
BRYOFLAM is conducting original research on bryophytes, a group of plants suited to the harsh climate in northern regions and whose potential has gone largely unexplored in inflammatory pharmacology. The project is also contributing to the discovery of promising new therapies.
This project – led in partnership with Plant Advanced Technologies (PAT) and the laboratory IMoPA-CNRS at University of Lorraine – has been selected for the “Projets collaboratifs I-Demo régionalisé” (I-Demo Regional Collaborative Projects) program.
This initiative is supported by the Grand Est regional authority and the French government (France 2030), as well as the European Union (European Regional Development Fund – ERDF).
B4B – Biomolecules for the bioeconomy
2024-2034 | 23 laboratories and 27 industrial partners
The Chaire B4B (Biomolecules for the bioeconomy) is led by the Lorraine University of Excellence. ETAP-LAB is a member of this Chair made up of 23 laboratories, with over 150 researchers and 27 industrial partners.
The food, cosmetic, and pharmaceutical sectors are the priority markets targeted for the biomolecules under study, with substances exhibiting antioxidant, antiproliferative, and anti-inflammatory properties. The program is focused on the discovery and production of biomolecules and their functionalization, vectorization, formulation, and controlled release.
This project is supported by France 2030 and the Grand Est regional authority.
Our previous collaborative programs
Partner of renowned academic laboratories
ETAP-LAB has established a network of world-class academic partner laboratories that provide support with the company’s scientific developments:
PhIND Laboratory
led by Prof. Denis Vivien (UMR 1237, INSERM/UNICAEN, Caen)
Laboratory of Experimental Cardiovascular Physiology
led by Prof. Cyril Reboul (SFR 4241 Tersys, INRA-UA, Avignon)
IMoPA Laboratory
led by Prof. Bruneau Charpentier (UMR 7365 CNRS-UL, Nancy)
N-GERE Laboratory
led by Prof. David Meyre (UMRS U1256, INSERM/UL, Nancy)
ETAP-LAB would like to thank all its supporters.
ETAP-LAB is currently a partner in various research projects funded by the French government, regional authorities, and the European Union.
